Shots:
- Rezolute has completed enrolment in the P-III (upLIFT) trial assessing ersodetug in 16 pts with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI), with topline data expected mid-Dec 2026
- Earlier this year, 7 of 8 pts enrolled in the study’s first half met the 1EP responder criterion, with all 7 achieving complete discontinuation of IV glucose following ersodetug administration
- The company will continue its expanded access program to provide ersodetug under compassionate use to pts with severe, treatment-resistant hypoglycemia caused by tumor-related HI
Ref: Globenewswire | Image: Rezolute | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
